肝细胞癌肿瘤标志物的研究进展

杨贵敏; 赵运胜; 王春华; 金亮

doi:10.3969/j.issn.1001-5256.2018.01.044

肝细胞癌肿瘤标志物的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.01.044

1. 河北省保定市儿童医院检验科
2. 河北省秦皇岛市第一医院检验科

基金项目:

秦皇岛市科技计划项目(201602A108)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2594
- HTML全文浏览量: 62
- PDF下载量: 513
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

Research advances in tumor markers for the diagnosis of hepatocellular carcinoma

Department of Clinical Laboratory, Baoding Children′s Hospital, Baoding, Hebei 071000, China

Research funding:

摘要

摘要: AFP是目前最常用的肝细胞癌(HCC)诊断标志物,但其敏感度和特异度均不够理想,尤其在HCC的早期阶段肿块较小时容易漏检。就目前出现的一些新的肿瘤标志物在HCC诊断、治疗监测和预后判断方面的临床价值进行归纳总结,并分析了HCC肿瘤标志物今后的发展趋势。认为多种肿瘤标志物联合检测有利于提高HCC诊断的敏感度和特异度,筛选和优化肿瘤检测组合、寻找无创且高效的肿瘤标志物及个性化治疗将是今后的研究热点。
- 癌,肝细胞 /
- 肿瘤标记,生物学 /
- 诊断 /
- 综述
Abstract: Hepatocellular carcinoma ( HCC) is a malignant tumor with a high fatality rate in the world, and alpha-fetoprotein ( AFP) is the most commonly used tumor marker for HCC diagnosis. However, AFP does not have a satisfactory sensitivity or specificity and may lead to missed diagnosis when the tumor is small in the early stage of HCC. This article summarizes the clinical value of new tumor markers in the diagnosis, treatment monitoring, and prognosis judgment of HCC and analyzes the future prospects of the measurement of tumor markers for HCC. It is pointed out that combined determination of several tumor markers helps to improve the sensitivity and specificity of HCC diagnosis, and the screening and optimization of combined determination of tumor markers, noninvasive and efficient tumor markers, and individualized treatment are research hotspots in future.
- carcinoma, hepatocellular /
- tumor markers, biological /
- diagnosis /
- review

HTML全文

参考文献(38)

[1]JOHNSON PJ.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J].Clin Liver Dis, 2001, 5 (1) :145-159.

[2]JIANG K, LI W, SHANG S, et al.Aberrant expression of Golgi protein 73 is indicative of a poor outcome in hepatocellular carcinoma[J].Oncol Rep, 2016, 35 (4) :2141-2150.

[3]SAI W, WANG L, ZHENG W, et al.Abnormal expression of Golgi protein 73 in clinical values and their role in HBV-related hepatocellular carcinoma diagnosis and prognosis[J].Hepat Mon, 2015, 15 (12) :e32918.

[4]MAO Y, YANG H, XU H, et al.Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J].Gut, 2010, 59 (12) :1687-1693.

[5]LIU T, YAO M, LIU S, et al.Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma[J].Oncotarget, 2017, 8 (10) :16498-16506.

[6]ZHAO YS, WANG M, CUI CY, et al.Clinical significance of eight serum indexes in diagnosis of primary hepatic carcinoma[J].Chongqing Med, 2014, 43 (2) :214-216. (in Chinese) 赵运胜, 王猛, 崔辰莹, 等.评价8种血清标志物在原发性肝癌诊断中的临床价值[J].重庆医学, 2014, 43 (2) :214-216.

[7]ZHAO Y, WANG M, CUI C, et al.Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma[J].Cancer Biomark, 2015, 15 (5) :677-683.

[8]KUMADA T, NAKANO S, TAKEDA I, et al.Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:special reference to imaging diagnosis[J].J Hepatol, 1999, 30 (1) :125-130.

[9]ZHANG Z, ZHANG Y, WANG Y, et al.Alpha-fetoprotein-L3and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J].Onco Targets Ther, 2015, 9:123-129.

[10]YI X, YU S, BAO Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma:a meta-analysis[J].Clin Chim Acta, 2013, 425:212-220.

[11]FILMUS J, CAPURRO M.Glypican-3:a marker and a therapeutic target in hepatocellular carcinoma[J].FEBS J, 2013, 280 (10) :2471-2476.

[12]JEON Y, KIM H, JANG ES, et al.Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients[J].APMIS, 2016, 124 (3) :208-215.

[13]WAN HG, XU H, GU YM, et al.Comparison osteopontin vs AFP for the diagnosis of HCC:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2014, 38 (6) :706-714.

[14]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.

[15]DONG ZZ, YAO DF, ZOU L, et al.An evaluation of transforming growth factor-beta 1 in diagnosing hepatocellular carcinoma and metastasis[J].Chin J Hepatol, 2007, 15 (7) :503-508. (in Chinese) 董志珍, 姚登福, 邹黎, 等.转化生长因子β1诊断肝癌和肝癌监测转移的临床价值[J].中华肝脏病杂志, 2007, 15 (7) :503

[16]YASMIN ANUM MY, LOOI ML, NOR AINI AH, et al.Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia[J].Med J Malaysia, 2009, 64 (3) :223-227.

[17]QIU LW, YAO DF, ZONG L, et al.Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development[J].Hepatobiliary Pancreat Dis Int, 2008, 7 (4) :406-411.

[18]ELMASHAD N, IBRAHIM WS, MAYAH WW, et al.Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma[J].Asian Pac J Cancer Prev, 2015, 16 (2) :613-619.

[19]YAMAGAMIM H, MORIYAMA M, MATSUMURA H, et al.Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases[J].Cancer, 2002, 95 (4) :824-834.

[20]LIN H, ZHENG WD.The diagnostic and prognostic value of AFP, AFU, TSGF and IL-8 in liver transplantation patients with liver cancer[J].J Clin Exp Med, 2017, 16 (8) :776-780. (in Chinese) 林花, 郑卫东.AFP、AFU、TSGF及IL-8对肝癌患者诊断及肝移植术预后评估的价值研究[J].临床和实验医学杂志, 2017, 16 (8) :776-780.

[21]JI J, WANG H, LI Y, et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versusα-fetoprotein for hepatitis B virusrelated hepatocellular carcinoma in China:a large-scale, multicentre study[J].PLo S One, 2016, 11 (4) :e0153227.

[22]MARRERO JA, FENG Z, WANG Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.

[23]ZHANG SY, LIN BD, LI BR.Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1with ROC and logistic regression for hepatocellular carcinoma[J].FEBS Open Bio, 2015, 5:240-244.

[24]GAO C, FANG L, YAO SK.Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (9) :921-925. (in Chinese) 高春, 房龙, 姚树坤.γ-谷氨酰转肽酶和甲胎蛋白表达的相关性及其在肝细胞癌诊断中的价值[J].临床肝胆病杂志, 2014, 30 (9) :921-925.

[25]YANG L, RONG W, XIAO T, et al.Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma[J].Sci China Life Sci, 2013, 56 (7) :638-646.

[26]YANG L, RONG W, XIAO T, et al.Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma[J].Sci China Life Sci, 2013, 56 (7) :638-646.

[27]SOYEMI OM, OTEGBAYO JA, OLA SO, et al.Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma[J].BMC Res Notes, 2012, 5:403.

[28]MOSSAD NA, MAHMOUD EH, OSMAN EA, et al.Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma[J].Tumor Biol, 2014, 35 (11) :11559-11564.

[29]ZHOU J, YU L, GAO X, et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol, 2011, 29 (36) :4781-4788.

[30]SUN YF, XU Y, YANG XR, et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J].Hepatology, 2013, 57 (4) :1458-1468.

[31]YOON SK, LIM NK, HA SA, et al.The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma[J].Cancer Res, 2004, 64 (15) :5434-5441.

[32]YANG Y, ZHANG GX, SHI RH, et al.Overexpression of HCCR in hepatocellular carcinoma cells and its clinical significance[J].Chin J Hepatol, 2007, 15 (3) :223-224. (in Chinese) 杨杨, 张国新, 施瑞华, 等.人宫颈癌基因蛋白在人肝细胞癌中的表达及其临床意义[J].中华肝脏病杂志, 2007, 15 (3) :223-224.

[33]LI JY, SONG JY, WANG JF, et al.Value of combined detection of AFP, CA19-9, and CEA in early diagnosis of primary liver cancer[J].J Clin Hepatol, 2017, 33 (7) :1291-1295. (in Chinese) 李嘉妍, 宋金云, 王建芳, 等.AFP、CA19-9、CEA联合检测对原发性肝癌的早期诊断价值[J].临床肝胆病杂志, 2017, 33 (7) :1291-1295.

[34]ZHU B, XIAO YX, PENG YS, et al.Values of combined detection of GPC3 and AFP in diagnosis of primary liver cancer[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :110-112. (in Chinese) 朱波, 肖亚雄, 彭宇生, 等.GPC3和AFP联合检测在原发性肝癌诊断中的价值[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :110-112.

[35]ZHANG XM, WEI MJ, XU ZJ, et al.Pattern of serumα-fetal protein, intereleukin-6 and Golgi protein 73 expressed in liver diseases and their diagnostic value on hepatocellular carcinoma[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (4) :339-344. (in Chinese) 张小曼, 魏梅娟, 许正锯, 等.血清甲胎蛋白、白细胞介素-6和高尔基体蛋白73在肝脏疾病中的表达特点及其对肝细胞癌的诊断价值[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (4) :339-344.

[36]HU Q, HUANG Y, WANG Z, et al.Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry coupled with an artificial neural network model for the diagnosis of hepatocellular carcinoma[J].Hepatogastroenterology, 2012, 59 (118) :1902-1906.

[37]ZHANG X, THIEFIN G, GOBINET C, et al.Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy:toward a new diagnostic tool of hepatocellular carcinoma[J].Transl Res, 2013, 162 (5) :279-286.

[38]WILHELM SM, ADNANE L, NEWELL P, et al.Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J].Mol Cancer Ther, 2008, 7 (10) :3129-3140.

施引文献

资源附件(0)

访问统计